Adoption of Innovations in Private Alcohol and Drug Treatment Centers in the United States [Restricted-Use], 2009-2013 (ICPSR 37621)

Version Date: Aug 12, 2020 View help for published

Principal Investigator(s): View help for Principal Investigator(s)
Paul M. Roman, University of Georgia; Lydia Aletraris, University of Georgia. Center for Research on Behavioral Health and Human Services Delivery. Owens Institute for Behavioral Research

https://doi.org/10.3886/ICPSR37621.v1

Version V1

Slide tabs to view more

Adoption of Innovations in Private Alcohol and Drug Treatment Centers is a multi-wave longitudinal study conducted between 2009 and 2013. The study goal was to measure the adoption and implementation of evidence-based treatment practices in treatment centers that received more than 50 percent of their total operational funding from sources that were not guaranteed from year to year. This definition is based on the concept of entrepreneurship, namely the necessity for the treatment organization to respond to changing conditions in the external political and economic environment in order to obtain half or more of its funding. The innovations considered are of three types usually specific to organizations treating substance use disorders:

  • medication-assisted treatments
  • psychosocial treatments
  • managerial practices

This data set consists of one of the multiple "waves" of data collection. The data was collected at four points in time. The baseline data, collected from June 2009 through October 2011 from 327 treatment centers, were obtained through face-to-face onsite interviews ranging from 1 to 4 hours in duration. These interviews were conducted with administrators of the respective treatment centers. In 70 of the 327 treatment centers, an administrator of the overall center and the administrator of clinical operations separately completed administrative and clinical interviews. In the remaining 257 centers, all of the administrative and clinical data were collected from the administrator of the overall center since there was no specialized administrator of clinical operations. The baseline data available here merge the data collected through these two different procedures so that the variables measured are identical for all centers regardless of the procedure.

The collected data include detailed information on Medication Assisted Treatment (MAT) and other treatment strategies used by the center to treat opioid use disorder (OUD) and alcohol use disorder (AUD). In cases where medications were not used by a center questions were asked for reasons why available medications were not used in treatment. Other sections of the interviews covered data on the organizations, their management, and other clinical practices implemented for OUD, AUD, and substance use disorder (SUD).

Three follow-up interviews were conducted via telephone at six month intervals following the previous interview. These follow-up interviews were much shorter compared to the baseline interview. The interviews centered on key changes in the center's operation and on the adoption of key innovations. But a focus of the follow-up interviews still focused on medications provided for treatment.

Roman, Paul M., and Aletraris, Lydia. Adoption of Innovations in Private Alcohol and Drug Treatment Centers in the United States [Restricted-Use], 2009-2013. Inter-university Consortium for Political and Social Research [distributor], 2020-08-12. https://doi.org/10.3886/ICPSR37621.v1

Export Citation:

  • RIS (generic format for RefWorks, EndNote, etc.)
  • EndNote
United States Department of Health and Human Services. National Institutes of Health. National Institute on Drug Abuse (R37 DA 013110)

Users are reminded that these data are to be used solely for statistical analysis and reporting of aggregated information, and not for the investigation of specific individuals or organizations.

Users interested in obtaining the restricted data must complete a Restricted Data Use Agreement, specify the reasons for the request, and obtain IRB approval or notice of exemption for their research. Please read the FAQ and tutorial on requesting restricted data for more information.

Inter-university Consortium for Political and Social Research
Hide

2009 -- 2013
2009 -- 2013
  1. The baseline on-site interviews took place between June 2009 and October 2011. The three follow-up interviews via telephone were conducted six months after the previous interview.

  2. Not all centers participated during each of the three follow-up phone interviews. However, all four datasets include 327 cases. Datasets can be linked together using the variable CID which is the Center ID.
    • 62 centers (19.0 percent) participated in none of the 3 follow-up interviews
    • 70 centers (21.4 percent) participated in a single follow-up interview (42 at 6 month / 17 at 12 month / 11 at 18 month)
    • 96 centers (29.4 percent) participated in 2 of the 3 follow-up interviews (49 at 6 and 12 month / 18 at 6 and 18 month / 29 at 12 and 18 month)
    • 99 centers (30.3 percent) participated in all 3 follow-up interviews
  3. On multiple occasions throughout the data, open-ended questions are coded to include statements from respondents. These data were not collected verbatim and have been edited from the "shorthand" provided by field interviewers to make coherent statements. Thus these wordings can be analyzed for content, but should not be subjected to data techniques reserved for analyses of verbatim quotations or recordings.

  4. The two questionnaires (administrator and clinical operations) for the baseline data (DS1) were merged into a single document.

Hide

The purpose of this data collection was to investigate the organizational structure and managerial practices within substance use disorder (SUD) treatment organizations to increase the utilization of evidence-based practices (EBP) for SUD.

Another purpose was to measure the adoption and implementation of evidence-based treatment practices in treatment centers that received more than 50 percent of their total operational funding from sources that were not guaranteed from year to year.

A sample of 450 SUD treatment centers was drawn through a multi-level sampling technique using combinations of censuses of SUD treatment organizations and population density across the U.S. as part of a larger data collection effort about the adoption and implementation of evidence based practices for the treatment of SUD. This sampling technique was followed by intensive telephone screening to construct sampling universes and eliminate ineligible SUD treatment centers. Eligibility included a minimum size requirement, multiple staff, dependence on a least 50 percent of income generated from unsecured sources, and presence of multiple levels of SUD care as prescribed by the American Society of Addiction Medicine (ASAM) standards of care. Centers not open to all community members were also excluded (e.g, Veterans Administration and prison based). The "waves" are lodged in longitudinal designs, not a panel design, with replacements comparable to those lost added for treatment centers that had closed or refused to participate. The baseline data for this collection that begun in June 2009 included 327 treatment centers.

Longitudinal: Panel

Substance abuse treatment centers in the contiguous 48 states and the District of Columbia.

Organization

The baseline on-site interview with administrators and clinicians focused on four things to provide evidence for adoption and implementation of innovations to improve treatment outcomes. These included:

  • External environments surrounding the organization
  • Organizatonal structure and production (treatment) processes
  • Patterns of organizational management and leadership
  • Characteristics, practices, and attitudes of counselors in implementing core technologies in the production (treatment) processes

The three follow-up interviews primarily ask the center administrator about the use of medications within the center. The medications asked about include:

  • Antabuse (disulfiram)
  • Methadone
  • Buprenorphine (Subutex or Suboxone)
  • Acamprosate (Campral)
  • Naltrexone (tablet)
  • Naltrexone (injectable - Vivitrol)
  • Topamax (topiramate)

Some variation exists between medications and across the interviews on the specific details concerning each medication asked about. However, the questions asked consistently across the medications include:

  • Does the center prescribe (medication)?
  • What percentage of patients receive (medication)?
  • If use of (medication) was discontinued, why was it discontinued?
  • If there was a large decrease in the percentage of patients being prescribed (medication), why was that the case?

Other sections of the survey instruments ask about the center's caseload (counts and percentages), and the administrator's knowledge / familiarity of various programs and legislation and how those things affect the center.

  • 6 month: 63.6 percent (208 out of 327 centers)
  • 12 month: 59.3 percent (194 out of 327 centers)
  • 18 month: 48.0 percent (157 out of 327 centers)

Hide

2020-08-12

2020-08-12 ICPSR data undergo a confidentiality review and are altered when necessary to limit the risk of disclosure. ICPSR also routinely creates ready-to-go data files along with setups in the major statistical software formats as well as standard codebooks to accompany the data. In addition to these procedures, ICPSR performed the following processing steps for this data collection:

  • Checked for undocumented or out-of-range codes.

Hide

No weight variables are present in the datasets.

Hide

Notes

  • The public-use data files in this collection are available for access by the general public. Access does not require affiliation with an ICPSR member institution.

  • One or more files in this data collection have special restrictions. Restricted data files are not available for direct download from the website; click on the Restricted Data button to learn more.